CHEMOCENTRYX, INC. (NASDAQ:CCXI) Files An 8-K Results of Operations and Financial Condition
Item2.02
|
Results of Operations and Financial Condition. |
On May10, 2017, ChemoCentryx, Inc. issued a press release
announcing its financial results for the first quarter ended
March31, 2017. A copy of this press release is attached hereto as
Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the
information in this Current Report on Form 8-K, including Exhibit
99.1, shall not be deemed filed for purposes of Section18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act),
or otherwise subject to the liability of that section, nor shall
it be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, whether
made before or after the date hereof, except as expressly set
forth by specific reference in such filing to this Current Report
on Form 8-K.
| Item9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits. |
|
Exhibit No. |
Description |
|
| 99.1 | Press Release, dated May 10, 2017 |
About CHEMOCENTRYX, INC. (NASDAQ:CCXI)
ChemoCentryx, Inc. (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors. Each of its drug candidates is a small molecule designed to target a specific chemokine or chemoattractant receptor, thereby blocking the negative inflammatory or suppressive response driven by that particular receptor, while leaving the rest of the immune system intact. The Company’s pipeline comprises various programs, including orphan and rare diseases, immuno-oncology, chronic kidney disease, and other inflammatory and autoimmune diseases. CHEMOCENTRYX, INC. (NASDAQ:CCXI) Recent Trading Information
CHEMOCENTRYX, INC. (NASDAQ:CCXI) closed its last trading session up +0.02 at 7.08 with 55,286 shares trading hands.